Journal of Thoracic Oncology:
Scientific Committee Co-Chairs
On behalf of The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), it gives us great pleasure to welcome you to the 2nd European Lung Cancer Conference, 28 April-1 May 2010 in Geneva, Switzerland.
After a very successful inaugural Conference in 2008, both Societies agreed that a regular scientific and educational meeting in this area is important for providing a comprehensive overview of the most significant advances in lung cancer research and treatment. Over the past few years, molecular biology has revolutionized everything we have ever known about the natural history of this illness. Treatment must be approached by multiple specialists and the strategy must be tailored for every patient. As such attendees at this Conference will be joined by leading specialists from different latitudes of the world in order to exchange knowledge and experience.
The program has interactive formats, which include debates on controversial topics, educational and keynote lectures, meet the expert sessions and specialty-specific workshops. Attendance at this 2nd European Lung Cancer Conference will be a rewarding experience in enhancing positive interactions between all lung cancer-related disciplines. The Scientific Committee is delighted to be in a position to encourage poster sessions and discussions and oral presentations on perspectives, ideas, results and research solutions submitted to promote an integrated approach to diagnosis and treatment of lung cancer.
In addition to the high quality scientific presentations, the Committee introduced several improvements to the Conference program, with the aim of providing a comprehensive overview necessary for clinicians to fully understand how to utilize and interpret advances in various molecular, genetic, pharmacogenomic, pathology and imaging methods and assessments; ensuring that the latest best practices and valuable key points/messages presented by the faculty can be put into clinical practice today. Our aim is to deliver an outstanding program with the right balance of clinical relevance, so an important part of the program covers the entire spectrum of practice issues in lung cancer.
The Conference will discuss current trends in surgical, radiotherapeutic and chemotherapeutic approaches to lung cancer with ongoing focus on the individualization of therapy based on clinical, histologic and molecular characteristics. The Conference format is designed to enhance discussion about early stages of lung cancer from the aspect of different potential treatments and combined modalities with specific questions about the role of surgery. The program also highlights the role of radiation in lung cancer treatment and the formidable development of new techniques such as stereotactic body, image-guided and intensity-modulated radiation therapy. The Conference will also feature presentations on optimizing the application of established targeted agents as well as presentations introducing emerging targeted agents, including mechanisms of action and preclinical/clinical results.
We trust that participants will highly value the scope and depth of the information on tumor biology, pathology, prevention, early detection, epidemiology, tobacco control, imaging, staging, management-related issues and translational and clinical research, presented with the emphasis on interdisciplinary challenges and supported by clinical interpretations needed for application of recent studies.
Our sincere thanks go to the members of the scientific committee, invited speakers, Conference organizers and sponsors for their commitment to this Conference. We hope that you enjoy the meeting and will already make a note in your diary for the 3rd edition in 2012.
Scientific Committee Co-Chairs